Excited to attend the Piper Sandler 36th Annual Healthcare Conference, held from 3-5 Dec in NYC! We’ll share how #NodThera’s #NLRP3 inflammasome inhibitors are transforming #cardiometabolic & #neurodegenerative disease treatment. Let’s connect! #Networking #Inflammation

NodThera has been featured in Citeline 's latest article on obesity and the current innovative approaches to obesity treatment. Read the full article here: lnkd.in/dHTAhk67 #NodThera #Obesity #Inflammation #Innovation

This year highlighted the broad therapeutic promise of brain-penetrant #NLRP3 #inflammasome inhibitors. Our VP of Medicinal Chemistry, David Harrison shares insights in #JMedChem on this evolving therapeutic landscape. Read here: doi.org/10.1021/acs.jm…

Dan Swisher, CEO, will participating in the 'BioPharma Dealmaking: Building the Pipeline' panel alongside leading #BioPharma experts at #Sach_BOIF. Join him to learn more about the key strategies shaping the #obesity treatment space: sachsforum.com/1boif-about.ht… #Conference #NLRP3

Our CEO, Dan Swisher, will be participating in a panel discussion and 1-1 meetings at the Guggenheim SMID Cap #Biotech #Conference in New York City on 6 February. Please get in touch if you would like to connect. #NLRP3 #Inflammasome #Inflammation

Our CEO, Dan Swisher, recently sat down with Trinity Chavez, Lead Anchor at NYSE 🏛, to share our plans for 2025. To learn more, watch the full conversation on #TakingStock: youtube.com/watch?v=EKdZUC… #NLRP3 #Inflammation #Inflammasome

NodThera’s management team will be in Miami on 10 March to participate in 1-1 #investor meetings at the Leerink Partners 2025 Global #Healthcare Conference. If you would like to learn more about our work, please reach out to set up a meeting. #Inflammation #NLRP3 #biotech

Meet us at BIO-Europe Spring next week! Excited to connect on NodThera’s #NLRP3 #inflammasome inhibitors, tackling chronic inflammation at it’s source. Let’s meet in Milan! #NodThera #BioEuropeSpring #Networking #Conference #Biotech

On 27 March, David Harrison, VP, Medicinal Chemistry, will presenting at the #ACSSpring2025 Meeting & Expo. Be sure to stop by to learn more about the journey of lead brain-penetrant #NLRP3 #inflammasome inhibitor NT-0796 from discovery through to #ClinicalDevelopment. #Biotech

NodThera will participate in a #FiresideChat at the 2ndAnnual Piper Sandler Virtual Cardio Symposium, held from 1-2 April. Join to learn more about our pioneering #NLRP3 #inflammasome targeting approach for the treatment of conditions driven by chronic #inflammation. #biotech

New data has been published in the #research journal Obesity (The Obesity Society), demonstrating the potential of NT-0796, our oral #NLRP3 #inflammasome inhibitor, to induce healthier and sustained weight loss in combination with GLP-1 receptor agonist: nodthera.com/news/nodtheras…

We have reached a major milestone, dosing the first patients in our Phase 2 RESOLVE-1 #ClinicalTrial investigating the potential of our lead candidate and oral #NLRP3 #inflammasome inhibitor, NT-0796. Read the full announcement here: nodthera.com/news/nodthera-…

In a new article in MedNous, Alan Watt, President & Chief Scientific Officer, discusses our recently initiated Phase 2 RESOLVE-1 #ClinicalTrial, evaluating #NLRP3 #inflammasome inhibitor NT-0796 in patients with #obesity: mednous.com/news/nodthera-… #Biotech #NodThera #Innovation

Please join us in welcoming Elisabeth Björk to NodThera’s Board of Directors! Elisabeth brings more than 20 years of pharmaceutical #leadership experience, with key areas of strength in #obesity and cardiometabolic disease. For more: nodthera.com/news/nodthera-…

Register now to hear our CEO, Dan Swisher, speak on the potential of NT-0796, our lead #NLRP3 #Inflammasome inhibitor, to deliver sustained and healthy weight loss in a #FireSideChat at the Piper Sandler Virtual #Obesity Symposium with ADA Takeaways: events.zoom.us/ev/AooXOwZPdlD…

Great to see our CEO Daniel Swisher in conversation with @BiotechTVHQ yesterday, discussing progress within our #pipeline of #NLRP3 #inflammasome inhibitors and their potential to transform treatment of diseases driven by chronic low-grade #inflammation biotechtv.com/post/nodthera-…

We're excited to attend the Obesity Science & Innovation Congress! Nick Clarke, Ph.D., NodThera’s Chief Development Officer, will present an overview of our novel approach to #obesitytherapeutics. Learn more about our science: nodthera.com/science

On #WorldHeartDay, we’re highlighting our commitment to treating #cardiovascular (CV) diseases. Learn more about our clinical trial in patients with #obesity and CV risk, and how our targeted approach is re-imagining how these diseases are treated: bit.ly/3KDB2q2

Tomorrow, Dr. Jyothis George MBBS PhD FRCP FACE M.D., Ph.D., FRCP, FACE, CMO of NodThera will present on the “Obesity & Related Conditions Panel: Advanced Therapeutics” at the 25thAnnual Biotech in Europe Forum (#Sachs_BEF) hosted by Sachs Associates. Learn more: bit.ly/3VKSgEn

Today, NodThera is participating in the 5thAnnual Needham Private Biotech and MedTech Company Virtual 1x1 Forum. We look forward to meeting with #investors to discuss our best-in-class pipeline of #NLRP3 #inflammasome inhibitors. Learn more: bit.ly/3KsG09b